David Will’s practice focuses on capital markets and securities law. He represents both public and private companies in a wide range of industries, including technology, financial services, healthcare and life sciences. He has advised companies in North America, Europe and Asia on a variety of securities law matters and ongoing reporting obligations. 

Download full bio 


  • Braze – $572 Million IPO 

  • Exscientia – $510.4 Million IPO 

  • Molecular Partners – $64 Million IPO 

  • Finch Therapeutics – $128 Million IPO 

  • LAVA Therapeutics – $107 Million IPO 

  • View all


  • University of Virginia School of Law
    JD, 2017

  • Princeton University
    BA, Religion

Admissions & Credentials

New York

Media & Insight